JP2024525145A5 - - Google Patents
Info
- Publication number
- JP2024525145A5 JP2024525145A5 JP2023576415A JP2023576415A JP2024525145A5 JP 2024525145 A5 JP2024525145 A5 JP 2024525145A5 JP 2023576415 A JP2023576415 A JP 2023576415A JP 2023576415 A JP2023576415 A JP 2023576415A JP 2024525145 A5 JP2024525145 A5 JP 2024525145A5
- Authority
- JP
- Japan
- Prior art keywords
- leukemia
- pharmaceutical composition
- composition according
- compound
- acute
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021100466 | 2021-06-17 | ||
| CNPCT/CN2021/100466 | 2021-06-17 | ||
| CN2022091677 | 2022-05-09 | ||
| CNPCT/CN2022/091677 | 2022-05-09 | ||
| PCT/CN2022/099089 WO2022262796A1 (en) | 2021-06-17 | 2022-06-16 | (r)-n-ethyl-5-fluoro-n-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-m ethylhexan-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide besylate salt for the treatment of diseases such as cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024525145A JP2024525145A (ja) | 2024-07-10 |
| JP2024525145A5 true JP2024525145A5 (cg-RX-API-DMAC7.html) | 2025-06-03 |
| JP7864745B2 JP7864745B2 (ja) | 2026-05-25 |
Family
ID=82196389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023576415A Active JP7864745B2 (ja) | 2021-06-17 | 2022-06-16 | がんなどの疾患の治療のための(r)-n-エチル-5-フルオロ-n-イソプロピル-2-((5-(2-(6-((2-メトキシエチル)(メチル)アミノ)-2-メチルヘキサン-3-イル)-2,6-ジアザスピロ[3.4]オクタン-6-イル)-1,2,4-トリアジン-6-イル)オキシ)ベンズアミドベシル酸塩 |
Country Status (16)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY38988A (es) | 2019-12-19 | 2021-06-30 | Janssen Pharmaceutica Nv | Derivados espiráncos sustituidos de cadena lineal |
| KR20250170131A (ko) | 2023-04-17 | 2025-12-04 | 얀센 파마슈티카 엔브이 | 조혈 장애를 치료하기 위한 메닌-ll1 억제제, dna 삽입제 및 피리미딘 유사체의 조합물 |
| KR20260099138A (ko) | 2023-10-20 | 2026-06-26 | 얀센 파마슈티카 엔브이 | 암 치료에 사용하기 위한, (r)-n-에틸-5-플루오로-n-아이소프로필-2-((5-(2-(6-((2-메톡시에틸)(메틸)아미노)-2-메틸헥산-3-일)-2,6-다이아자스피로[3.4]옥탄-6-일)-1,2,4-트라이아진-6-일)옥시)벤즈아미드, 이의 제제 및 이의 투여 요법 |
| KR20260115654A (ko) | 2023-12-04 | 2026-07-24 | 쇼우야오 홀딩스 (베이징) 코., 엘티디. | 치환된 다환 화합물 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010289321A1 (en) | 2009-09-04 | 2012-04-05 | The Regents Of The University Of Michigan | Compositions and methods for treatment of leukemia |
| AU2014249233A1 (en) | 2013-03-13 | 2015-09-24 | The Regents Of The University Of Michigan | Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof |
| USRE49687E1 (en) | 2014-09-09 | 2023-10-10 | The Regents Of The University Of Michigan | Thienopyrimidine and thienopyridine compounds and methods of use thereof |
| WO2016197027A1 (en) | 2015-06-04 | 2016-12-08 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with mll proteins |
| TWI703150B (zh) | 2015-06-04 | 2020-09-01 | 美商庫拉腫瘤技術股份有限公司 | 用於抑制menin及mll蛋白之交互作用的方法及組合物 |
| BR112018012707A2 (pt) * | 2015-12-22 | 2019-01-29 | Vitae Pharmaceuticals Inc | inibidores da interação de menin-mll |
| AU2017212572A1 (en) | 2016-01-26 | 2018-08-23 | Memorial Sloan-Kettering Cancer Center | Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia |
| WO2017161028A1 (en) | 2016-03-16 | 2017-09-21 | Kura Oncology, Inc. | Substituted inhibitors of menin-mll and methods of use |
| US10752639B2 (en) | 2016-03-16 | 2020-08-25 | Kura Oncology, Inc. | Bridged bicyclic inhibitors of menin-MLL and methods of use |
| CN109415337B (zh) | 2016-05-02 | 2022-01-18 | 密执安大学评议会 | 作为多发性内分泌腺瘤蛋白抑制剂的哌啶 |
| WO2017207387A1 (en) | 2016-05-31 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction |
| ES2831084T3 (es) | 2016-06-10 | 2021-06-07 | Vitae Pharmaceuticals Inc | Inhibidores de la interacción menina-MLL |
| WO2018024602A1 (en) | 2016-08-04 | 2018-02-08 | Bayer Aktiengesellschaft | 2,7-diazaspiro[4.4]nonanes |
| CA3033239A1 (en) | 2016-09-14 | 2018-03-22 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-mll interaction |
| TWI753016B (zh) | 2016-09-14 | 2022-01-21 | 比利時商健生藥品公司 | Menin-mll相互作用之稠合二環抑制劑 |
| CN118359610A (zh) | 2016-09-16 | 2024-07-19 | 生命医药有限责任公司 | Menin-mll相互作用的抑制剂 |
| WO2018106818A1 (en) | 2016-12-07 | 2018-06-14 | Kura Oncology, Inc. | Methods of promoting beta cell proliferation |
| WO2018106820A1 (en) | 2016-12-07 | 2018-06-14 | Kura Oncology, Inc. | Methods of promoting beta cell proliferation |
| EA201991448A1 (ru) | 2017-01-06 | 2019-12-30 | Янссен Фармацевтика Нв | Азепановые ингибиторы взаимодействия менин-mll |
| CN108456208B (zh) | 2017-02-22 | 2021-04-16 | 广州市恒诺康医药科技有限公司 | 氮杂螺环类化合物及其制备方法和应用 |
| CN110691779B (zh) | 2017-03-24 | 2023-10-10 | 库拉肿瘤学公司 | 治疗血液系统恶性肿瘤和尤因肉瘤的方法 |
| US11542248B2 (en) | 2017-06-08 | 2023-01-03 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
| TW201920170A (zh) | 2017-09-20 | 2019-06-01 | 美商庫拉腫瘤技術股份有限公司 | 經取代之menin-mll 抑制劑及使用方法 |
| JP2022503792A (ja) | 2018-09-26 | 2022-01-12 | クラ オンコロジー,インク. | メニン阻害剤を用いた血液悪性腫瘍の処置 |
| UY38988A (es) | 2019-12-19 | 2021-06-30 | Janssen Pharmaceutica Nv | Derivados espiráncos sustituidos de cadena lineal |
-
2022
- 2022-06-16 AU AU2022292697A patent/AU2022292697A1/en active Pending
- 2022-06-16 KR KR1020237043027A patent/KR20240021808A/ko active Pending
- 2022-06-16 MX MX2023014890A patent/MX2023014890A/es unknown
- 2022-06-16 EP EP22733288.9A patent/EP4355747A1/en active Pending
- 2022-06-16 CN CN202280043068.0A patent/CN117597348A/zh active Pending
- 2022-06-16 JP JP2023576415A patent/JP7864745B2/ja active Active
- 2022-06-16 CA CA3220099A patent/CA3220099A1/en active Pending
- 2022-06-16 CN CN202410890382.3A patent/CN118852178A/zh active Pending
- 2022-06-16 PE PE2023003361A patent/PE20240923A1/es unknown
- 2022-06-16 WO PCT/CN2022/099089 patent/WO2022262796A1/en not_active Ceased
- 2022-06-16 PH PH1/2023/553300A patent/PH12023553300A1/en unknown
- 2022-06-16 US US18/570,727 patent/US20260125387A1/en active Pending
- 2022-06-16 IL IL309359A patent/IL309359A/en unknown
- 2022-06-17 UY UY0001039823A patent/UY39823A/es unknown
-
2023
- 2023-11-28 DO DO2023000260A patent/DOP2023000260A/es unknown
- 2023-12-13 CL CL2023003731A patent/CL2023003731A1/es unknown
- 2023-12-28 CO CONC2023/0018577A patent/CO2023018577A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2606497C2 (ru) | Тиазолилфенилбензолсульфонамидопроизводные в качестве ингибиторов киназ | |
| RU2485122C2 (ru) | Соединения и композиции, ингибирующие parp, и способы их применения | |
| JP2015512942A5 (cg-RX-API-DMAC7.html) | ||
| CA2850564A1 (en) | Compounds useful as inhibitors of atr kinase | |
| EP2868660B1 (en) | Antitumor effect potentiator comprising an imidazooxazine compound | |
| US20090093495A1 (en) | Combination of a src kinase inhibitor and a bcr-abl inhibitor for the treatment of proliferative diseases | |
| CN105592850B (zh) | Ack1/tnk2酪氨酸激酶的抑制剂 | |
| US12084431B2 (en) | Pharmaceutical salts of pyrimidine derivatives and method of treating disorders | |
| WO2017049462A1 (zh) | 一类新型的flt3激酶抑制剂及其用途 | |
| TWI453201B (zh) | 可作為Hsp90之抑制劑之異吲哚衍生物 | |
| JP2022523368A5 (cg-RX-API-DMAC7.html) | ||
| CN112236426A (zh) | 制备2,4,5-三取代的1,2,4-三唑酮的方法 | |
| JP2025131661A (ja) | 2-(5-(4-(2-モルホリノエトキシ)フェニル)ピリジン-2-イル)-n-ベンジルアセトアミドの固体形態 | |
| CA2671336A1 (en) | Epothilone analogues modified at positions c12-c13 as anticancer drugs | |
| JP2012255038A (ja) | 異常な細胞増殖の治療用のピリミジン誘導体 | |
| CA3195465A1 (en) | Succinate and crystal form thereof as therapeutics | |
| TW202245746A (zh) | N-((r)-2,3-二羥基丙氧基)—3,4—二氟—2—(2—氟—4—碘—苯基胺基)—苯甲醯胺之基本上純的形式iv之組合物及其用途 | |
| CN113382997A (zh) | 盐酸罗加替尼的一水合物及其固体状态 | |
| EP4663628A1 (en) | New compound and pharmaceutical composition comprising same | |
| CN112442105B (zh) | 作为蛋白激酶抑制剂的嘧啶并[4,5-d]嘧啶-2-酮衍生物 | |
| WO2022083679A1 (en) | Prodrugs for sustained releasing therapeutic agents and uses thereof | |
| KR102759785B1 (ko) | CCL2 발현을 억제하는 1-aryloxymethyl-2,4,5-trifluorobenzene 유도체, 이의 제조방법 및 이를 포함하는 약학적 조성물 | |
| EP2924045A1 (en) | New agents for the treatment of cancer | |
| WO2016197981A1 (zh) | 氘代的3-[(6-喹啉基)二氟甲基]-6-[(1-甲基)-4-吡唑基][1,2,4]三唑并[4,3-b]哒嗪及其应用 | |
| HK40065028A (en) | The monohydrate of rogaratinib hydrochloride and solid states thereof |